Home Cart Sign in  
Chemical Structure| 95809-78-2 Chemical Structure| 95809-78-2

Structure of Devimistat
CAS No.: 95809-78-2

Chemical Structure| 95809-78-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CPI-613 is an E1α pyruvate dehydrogenase (PDH) modulator that prevents cancer cells from metabolizing glucose for energy. CPI-613 has been granted orphan drug status by the US FDA for pancreatic cancer.

Synonyms: CPI-613

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Devimistat

CAS No. :95809-78-2
Formula : C22H28O2S2
M.W : 388.59
SMILES Code : O=C(O)CCCCC(SCC1=CC=CC=C1)CCSCC2=CC=CC=C2
Synonyms :
CPI-613
MDL No. :MFCD22420826
InChI Key :ZYRLHJIMTROTBO-UHFFFAOYSA-N
Pubchem ID :24770514

Safety of Devimistat

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302+H312-H315-H318-H411
Precautionary Statements:P264-P270-P273-P280-P301+P312+P330-P302+P352+P312-P305+P351+P338+P310-P332+P313-P391-P501
Class:9
UN#:3077
Packing Group:

Isoform Comparison

Biological Activity

Target
  • Dehydrogenase

In Vitro:

Cell Line
Concentration Treated Time Description References
HN6 100 µM 24 hours To evaluate the effect of CPI-613 on ATP production in HNSCC cells, results showed that CPI-613 reduced ATP production J Exp Clin Cancer Res. 2021 Dec 14;40(1):393.
HN31 100 µM 24 hours To evaluate the effect of CPI-613 on ATP production in HNSCC cells, results showed that CPI-613 reduced ATP production J Exp Clin Cancer Res. 2021 Dec 14;40(1):393.
KNS42 cells 100 µM 24 hours To evaluate the effect of CPI-613 on the transcriptome of KNS42 cells, the results showed that CPI-613 suppressed gene sets related to oxidative phosphorylation and respiratory chain complexes. JCI Insight. 2024 Mar 14;9(8):e172565.
Sk-Mel-5 300 µM 24 hours To detect the effect of CPI613 on glycolysis levels, the results showed that CPI613 significantly increased glycolysis levels, glycolytic capacity, and glycolytic reserve. J Immunother Cancer. 2023 Sep;11(9):e007146.
Pa03C 50 µM 24 hours To evaluate the effect of Devimistat on pancreatic cancer cell metabolism, results showed that Devimistat significantly reduced the utilization of TCA cycle substrates. J Exp Clin Cancer Res. 2021 Aug 10;40(1):251.
Panc10.05 50 µM 24 hours To evaluate the effect of Devimistat on pancreatic cancer cell metabolism, results showed that Devimistat significantly reduced the utilization of TCA cycle substrates. J Exp Clin Cancer Res. 2021 Aug 10;40(1):251.
B16F10 300 µM 48 hours To detect the effect of CPI613 on PD-L1 mRNA expression, the results showed that CPI613 significantly upregulated PD-L1 mRNA expression. J Immunother Cancer. 2023 Sep;11(9):e007146.
MCF7 150 µM 48 hours To evaluate the effect of CPI-613 on breast cancer cells, the results showed that the combination of CPI-613 with FRI-1 significantly increased cell death. Antioxidants (Basel). 2021 Oct 14;10(10):1618.
MDA-MB-231 150 µM 48 hours To evaluate the effect of CPI-613 on breast cancer cells, the results showed that the combination of CPI-613 with FRI-1 significantly increased cell death. Antioxidants (Basel). 2021 Oct 14;10(10):1618.
UWB1.289 MUT 75 µM 7 days CPI-613 treatment decreased CD133+ and CD117+ cell frequency and reduced sphere-forming capacity. Cancers (Basel). 2019 Oct 29;11(11):1678.
OVCAR3 75 µM 7 days CPI-613 treatment decreased CD133+ and CD117+ cell frequency and reduced sphere-forming capacity. Cancers (Basel). 2019 Oct 29;11(11):1678.
PANC-1 cells 1, 10, 50 µM 72 hours To evaluate the cytotoxicity of CPI-613 on PANC-1 cells, results showed that CPI-613 exhibited cytotoxicity at different concentrations. ACS Appl Mater Interfaces. 2019 Dec 11;11(49):45390-45403.
PaTu-8902 cells 50 µM 72 hours CPI-613 selectively kills cells adapted to acidosis through inhibition of the Krebs cycle and induction of oxidative stress, even in the presence of lactate. Int J Mol Sci. 2021 Oct 6;22(19):10790.
HeLa cells 50 µM 72 hours CPI-613 selectively kills cells adapted to acidosis through inhibition of the Krebs cycle and induction of oxidative stress, even in the presence of lactate. Int J Mol Sci. 2021 Oct 6;22(19):10790.
Hep G2 cells 50 µM 72 hours CPI-613 selectively kills cells adapted to acidosis through inhibition of the Krebs cycle and induction of oxidative stress, even in the presence of lactate. Int J Mol Sci. 2021 Oct 6;22(19):10790.
HDF cells 50 µM 72 hours CPI-613 selectively kills cells adapted to acidosis through inhibition of the Krebs cycle and induction of oxidative stress, even in the presence of lactate. Int J Mol Sci. 2021 Oct 6;22(19):10790.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NOD/SCID mice OVCAR3 xenograft model Intraperitoneal injection 12.5 mg/kg Once weekly for 2 weeks CPI-613 treatment decreased CD133+ and CD117+ cell frequency and inhibited tumor growth. Cancers (Basel). 2019 Oct 29;11(11):1678.
NSG mice Tongue tumor model Intraperitoneal injection 25 mg/kg Every 3 days for 2 weeks To evaluate the therapeutic effect of CPI-613 on the tongue tumor model, results showed that CPI-613 significantly inhibited tumor growth J Exp Clin Cancer Res. 2021 Dec 14;40(1):393.
Nude mice GBM12 xenograft model Intraperitoneal injection 50 mg/kg 3 times per week, continuous treatment To evaluate the tumor growth inhibitory effect of CPI-613 combined with ABT263 in the GBM12 xenograft model, the results showed that the combination treatment significantly inhibited tumor growth. JCI Insight. 2024 Mar 14;9(8):e172565.
NOD/SCIDγ(-/-) mice Pancreatic cancer xenograft model Oral 50 mg/kg Twice daily for 15 or 20 days To evaluate the antitumor effect of Devimistat on pancreatic cancer xenograft models, results showed that Devimistat significantly reduced tumor volume and weight. J Exp Clin Cancer Res. 2021 Aug 10;40(1):251.
Mice Orthotopic pancreatic cancer model Intravenous injection CPI-613 10 mg/kg, LY2109761 13.2 mg/kg Every 5 days for a total of 6 injections To evaluate the antitumor efficacy of the nanopolyplexes in a pancreatic cancer mouse model, results showed that the p-PPCL nanopolyplex significantly inhibited tumor growth. ACS Appl Mater Interfaces. 2019 Dec 11;11(49):45390-45403.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01034475 Advanced Hematologic Malignanc... More >>ies Less << PHASE1 COMPLETED 2025-08-14 Wake Forest University Health ... More >>Sciences, Winston-Salem, North Carolina, 27012, United States Less <<
NCT03793140 Lymphoma|Leukemia PHASE2 ACTIVE_NOT_RECRUITING 2025-12-25 City of Hope, Duarte, Californ... More >>ia, 91010, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, 07645, United States|Memorial Sloan Kettering Commack, Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester, Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, 11553, United States|University of Pennsylvania (Data Collection Only), Philadelphia, Pennsylvania, 19104, United States|Md Anderson Cancer Center, Houston, Texas, 77030, United States Less <<
NCT01520805 Acute Myeloid Leukemia (AML)|M... More >>yelodysplastic Syndrome (MDS) Less << PHASE2 WITHDRAWN 2025-12-18 Cornerstone Pharmaceuticals, I... More >>nc, Cranbury, New Jersey, 08512, United States Less <<
NCT00741403 Advanced Cancer|Metastatic Can... More >>cer|Lymphoma|Solid Tumors|Advanced Malignancies Less << PHASE1 COMPLETED 2025-12-16 Pivotal Research Centers, Peor... More >>ia, Arizona, 85381, United States|Eastchester Center for Cancer Care, Bronx, New York, 10469, United States|Mary Crowley Cancer Research Centers, Dallas, Texas, 75201, United States|British Columbia Cancer Agency, Vancouver, British Columbia, Canada Less <<
NCT01832857 Cancer PHASE2 TERMINATED 2025-12-16 Eastchester Center for Cancer ... More >>Care, Bronx, New York, 10469, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.57mL

0.51mL

0.26mL

12.87mL

2.57mL

1.29mL

25.73mL

5.15mL

2.57mL

References

[1]Zachar Z, Marecek J, et al. Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. J Mol Med (Berl). 2011 Nov;89(11):1137-48.

[2]Lee KC, Shorr R, et al. Formation and anti-tumor activity of uncommon in vitro and in vivo metabolites of CPI-613, a novel anti-tumor compound that selectively alters tumor energy metabolism. Drug Metab Lett. 2011 Aug;5(3):163-82.

[3]Stuart SD, Schauble A, et al. A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. Cancer Metab. 2014 Mar 10;2(1):4.

[4]Zachar Z, Marecek J, Maturo C, Gupta S, Stuart SD, Howell K, Schauble A, Lem J, Piramzadian A, Karnik S, Lee K, Rodriguez R, Shorr R, Bingham PM. Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. J Mol Med (Berl). 2011 Nov;89(11):1137-48. doi: 10.1007/s00109-011-0785-8. Epub 2011 Jul 19. PMID: 21769686.

[5]Lee KC, Shorr R, Rodriguez R, Maturo C, Boteju LW, Sheldon A. Formation and anti-tumor activity of uncommon in vitro and in vivo metabolites of CPI-613, a novel anti-tumor compound that selectively alters tumor energy metabolism. Drug Metab Lett. 2011 Aug;5(3):163-82. doi: 10.2174/187231211796904991. PMID: 21722089.

[6]Stuart SD, Schauble A, Gupta S, Kennedy AD, Keppler BR, Bingham PM, Zachar Z. A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. Cancer Metab. 2014 Mar 10;2(1):4. doi: 10.1186/2049-3002-2-4. PMID: 24612826; PMCID: PMC4108059.

 

Historical Records

Categories